How do we look for autoantibodies against a wide range of self antigens? The @aaronmring lab developed a high-throughput autoantibody discovery technique called Rapid Extracellular Antigen Profiling (REAP) against 2,770 extracellular and secreted proteins "exoproteome" 💪🏼 (2/n)
A large fraction of #COVID patients had autoantibodies to multiple self antigens. The more severe the disease, more autoantibodies they had.(3/n)
So what are the targets of these autoantibodies? It turns out to be many. Some antibodies bound to interferons, chemokine and cytokines, while others bound to proteins expressed on the surface of immune and non-immune cells. (4/n)
Here are the autoantigens that are detected by antibodies in COVID patients. Columns represent patients. Rows are antigens. Notice the frequency of anti-interferon antibodies in severe COVID patients! Very reminiscent of this study👇🏽 (5/n)
These autoantibodies to IFN-I are likely functional - people who have them were unable to control viral load, compared to those without - matched for comparable average age, sex, and disease severity. (6/n)
In addition to IFN-I, there were many other immune proteins that become target of antibody attack. IL-1α/β, IL-6, GM-CSF, IL-18Rβ, and Leptin (LEP). Chemokine autoantibody targets included CXCL1, CXCL7, CCL2, CCL15, CCL16, and the chemokine decoy receptor ACKR1. (7/n)
Surface autoantigens on immune cells also found; NKG2D ligands (RAET1E/L, ULBP1/2), NK cell receptors NKG2A/C/E (KLRC1/2/3), B cell-expressed proteins (CD38, FCMR, FCRL3, CXCR5), T cell expressed proteins (CD3E, CXCR3, CCR4), and myeloid expressed proteins (CCR2, CD300E).(8/n)
These Abs appear to be functional in vivo. People who had anti-B cell antibodies had very low number of circulating B cells and very low IgM response against RBD. (9/n)
One patient with autoantibodies against CD3E (a component of the T cell receptor complex) had intact B and NK cell compartments but dramatically reduced levels of
CD4 T cells, CD8 T cells, and NKT cells in the blood. (10/n)
Another way we validated the function of the autoantibodies is through the use of mouse model. Anti-IFNAR or anti-IL-18 Ab treatment of mice rendered them more susceptible to disease and death after #SARSCoV2 challenge. (11/n)
In addition to immune-related antigens, we also found antibodies to various tissue-specific antigens in organs like the central nervous system, vascular, connective tissues, liver, GI tract..etc. Such antibodies could drive damage in target tissues. (12/n)
Some of the autoantibodies were found from the very beginning of analysis, while others were induced during the course of study. Others declined in their levels over time. (13/n)
There are many unanswered questions. How long do these autoantibodies last? What damage do they cause? How are they induced? Do they occur in #LongCovid?
Here is a thread to explain the findings of this study, that used computational tools to predict T cell reactive sequences in #SARSCOV2 subunit vaccines.
Our adaptive immune system has 2 types of white blood cells known as lymphocytes. T cells and B cells. These lymphocytes give us protection from wide variety of pathogens. Each lymphocyte has unique receptor that detect specific features of a pathogen. (2/n)
B cells detect pathogens structures through antibodies. T cells cannot detect pathogens on their own. They can only “see” pathogen when tiny pieces of viral proteins (peptides) are presented by molecules called major histocompatibility complex (MHC). (3/n)
Do some people have cross-reactive antibodies to #SARSCoV2? If so, who are they? And are these cross-reactive Abs protective against #COVID19? A fascinating study by @KevinWNg et al provides answers. Thread. (1/n)
Do some people have cross-reactive antibodies? The answer is yes. SARS-CoV-2 Spike-reactive IgG was detected in 5 of 34 SARS-CoV-2-uninfected individuals with RT-qPCR-confirmed HCoV infection, as well as in 1 of 31 individuals without recent HCoV infection. (2/n)
Who has cross-reactive anti-spike antibodies? Mostly children and adolescents. The prevalence of SARS-CoV-2 S-reactive IgG antibodies peaked at 62% between 6 and 16 years of age. This age group is also the one in which antibodies to seasonal coronaviruses peak.(3/n)
So happy to see a paper by my graduate student, Daniel Kim, chosen as a spotlight for the @JVirology 👏🏼 Daniel found that HSV-1 genome binds to RUNX1 and represses transcription of viral genes - a possible viral strategy to achieve latent infection. (1/n)
Herpesviruses establish latent infection in neurons and leukocytes that express RUNX1 (transcription factor). Curiously, herpesvirus genomes are enriched in RUNX1 binding sites but not other viruses. (2/n)
Overexpression of RUNX1 but not RUNX3 (a related transcription factor that is not expressed in the cell type in which HSV-1 established latency) blunts HSV-1 infection in vitro. (3/n)
As we approach the cold winter months in the Northern Hemisphere, I want to share these movies of mucociliary clearance (MCC) in the trachea of mice housed at 10% vs. 50% relative humidity (RH). Captured by @ericsongg (1/n)
MCC is a key mechanism of removal of inhaled particles, including viruses and bacteria. It is a primary defense mechanism of the respiratory tract. The dry air dehydrates the mucus and periciliary layer, impairing MCC. (3/n)
In this new Commentary, @SaadOmer3 and I discuss the birth & evolution of vaccine science, how vaccinations have changed our world, the current state of vaccines, remaining challenges & future outlook. #VaccinesSaveLives (1/n)
Live attenuated vaccines worked well by themselves. But, immunization using toxoid alone induced poor immunity. #GastonRamon found that toxoid injected with ‘stuff’ incl. tapioca, lecithin, agar, starch oil, saponin or breadcrumbs improved immunity. (2/n)
While Alum became the adjuvant used in vaccines for past 100 years, there is a recent expansion in new adjuvants with potent capacity to boost immunity to vaccines. Discovery of pattern recognition receptors and their ligands laid foundation for this👇🏽 @YaleIBIO (3/n)
In the best case scenario, a rapid and robust induction of IFN-I should result in viral control and mild disease. This may happen in young people, or with low viral exposure settings. For a discussion we wrote, please read this.
(2/n) cell.com/cell-host-micr…
In older adults or after high dose viral exposure, impaired IFN response early during infection results in enhanced viral replication, and prolonged levels of IFN-I and IFN-III responses that could result in pathological consequences and severe disease. (3/n)